This Article  • References  • Full text PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Contact me when this article is cited  Related Content  • Similar articles in JAMA  Social Bookmarking   What's this?

Joseph F. Sadusk, Jr., MD; Paul A. Palmisano, MD

JAMA. 1965;194(9):987-989.

	Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings.

On April 22, 1965, the second meeting of an Ad Hoc Advisory Committee on the Teratogenic Effect of Certain Drugs was held under the auspices of the Food and Drug Administration in order to review available data related to the teratogenic effect of meclizine, cyclizine, and chlorcyclizine and to make recommendations regarding the dispensing status and labeling directions of drug articles containing the subject compounds. On July 27, 1965, the recommendations resulting from that meeting were transmitted to the medical director of the FDA by the chairman of the committee. (A list of the members appears at the end of this paper.) The present communication offers a summary of the scientific and clinical background considerations upon which the recommendations of the committee were based, and final decisions of the FDA in the matter.

Background Considerations

In the latter part of 1962, attention was drawn to the possibility of human fetal . . . [Full Text PDF of this Article]

Author Affiliations
From the Bureau of Medicine, Food and Drug Administration, US Department of Health, Education and Welfare, Washington, DC.

Footnotes
Read in part before the American Academy of Pediatrics, Chicago, Oct 26, 1965.

Reprint requests to Food and Drug Administration, US Department of Health, Education and Welfare, Washington, DC 20204 (Dr. Sadusk).

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?